reports of benefits from pulmonary artery pressure monitoring, especially in critically ill patients, are also accumulating. [20] [21] [22] [23] [24] [25] [26] [27] [28] However no controlled, prospective, randomized clinical trial has been performed to show that PA catheterization changes outcome in patients in whom it is used.293 ' We designed our study to answer two questions: 1. In patients with PVD, does the use of a PA catheter to 'optimize' LVF and oxygen transport (tune-up) preoperatively influence the clinical outcome? 2. How important is the length of time allowed for the preoperative tune-up?
Materials and Methods
Study Design A randomized, prospective, clinical trial was approved by the Committee on the Use of Human Subjects in Research at the University of Minnesota. Patients from a single surgical service, scheduled to receive an in situ vein graft bypass for limb salvage, made necessary by peripheral lower-extremity atherosclerotic arterial occlusive disease, were eligible to participate. All operations were performed by a single surgeon (DR Knighton). Patient eligibility was determined by the surgical intensive care unit (SICU) anesthesiologist (JF Berlauk/IJ Gilmour). The randomization for all study groups was generated by a randomnumber generator (Statworksg). Eligible patients were entered consecutively in order of their appearance on the surgical schedule. Patients with the following problems were excluded because these clinical settings have literature documentation that supports the use of the PA catheter during necessary surgical intervention: 1. Myocardial infarction (MI) within the previous 3 months. 3236 2. Coronary artery bypass graft (CABG) within the previous six weeks.37 3. Uncompensated congestive heart failure (CHF), 7'384' identified clinically by pedal edema, jugular venous distention, pulmonary rales, and chest x-ray (CXR) findings of pulmonary edema. 4 These adverse intraoperative events were chosen because there is documentation in the literature that they correlate with increased perioperative morbidity. Intraoperative events were recorded by the anesthetist on the anesthetic record and tabulated later. Those patients with a PA catheter had a hemodynamic profile measured at least every 2 hours during operation. The hemodynamic endpoints previously defined were maintained during anesthesia in groups 1 and 2.
Postoperative Management
All patients were continuously monitored in the SICU for at least 18 hours after operation. Major 
Laboratory Studies
Baseline studies for all patients included an blood chemistry admission battery, EKG, CXR, 12-hour creatinine clearance, and serum CPKMB. A CPKMB was drawn at the end of the preoperative assessment ofgroup 1. In all groups a CPKMB was drawn at the end of surgery and every 8 hours after operation. After operation an EKG, CXR, and 12-hour creatinine clearance were performed on all patients. We found no correlation between either the baseline hemodynamic profile or the hemodynamic response to therapy and subsequent complications in groups 1 and 2.
Data

Intraoperative Events
Sixty-six of eighty-nine patients (74%) received anesthetic care from a single SICU anesthesiologist; 81 of 89 patients (91 %) received anesthetic care from either oftwo SICU anesthesiologists.
After entry into the study, no patient was excluded but surgery was canceled for two patients in group 1, leaving 43 patients who completed the study ( restoration of blood flow and were placed on heparin. The grafts remained patent. None of these patients received a PA catheter.
Complications are summarized in Table 5 . Both groups of patients with a PA catheter had significantly fewer adverse intraoperative events (p < 0.05), less postoperative cardiac morbidity (p < 0.05), and less early graft thrombosis (p < 0.05) compared to the control group. The mortality rate was 9.5% in the control group and 1.5% in the combined groups of patients with a PA catheter.
Other Analysis
There were no significant differences between groups in baseline blood urea nitrogen (BUN), serum creatinine (Cr), blood lactate, or serum potassium (K+). There were no differences between groups in length of hospital stay (LOS) before surgery, LOS in the ICU, total hospital LOS, or total hospital charges (Table 6 ). Furthermore no differences were found between patients with a complication versus no complication, except control patients with complications spent 3.6 ± 2.9 days in the ICU compared to 1.9 ± 0.6 days if no complication occurred (p < 0.05). In addition the increased total hospital charges ($29,928 ± 14,078) for a complication in the control group offset any costs associated with PA catheter insertion in the SICU ($29,102 ± 13,207) or in the PIR ($23,770 + 12,418) (Table 6 ).
Discussion
Does 'optimizing' cardiovascular hemodynamics using a PA catheter improve outcome? To test this hypothesis, we chose to study surgical patients with PVD, a group known to be at high risk for perioperative cardiovascular complications.8 Because aortic and intraperitoneal surgery are associated with increased postoperative cardiac complications,32'33'38,39 only patients with peripheral vascular surgery for limb salvage were included. To help decrease the number of confounding clinical variables, the study used a single vascular surgeon, a single anesthetic technique, and a single SICU service.
Using the PA catheter to optimize a patient's preop- 5 32"3'5859 27% had a previous MI,6'7'39'47'60 15% had compensated CHF,7'38-4' and 11% had angina.633'39'4758 These risk factors were evenly distributed between groups except that no patient with angina was randomized to the control group. Although the randomization sequence was performed at the beginning ofthe study, actual patient entry into the study was finalized the evening before surgery. Bias of the chief surgical resident, who determined the operating room schedule, may account for the lack of patients with angina in the control group. While stable angina is controversial as a predictor of cardiac morbidity in the noncardiac surgical patient,6' its presence in the patient groups receiving a PA catheter imply that they may have had more CV disease than the control group. In this study we found that patients 'tuned up' before operation with a PA catheter had fewer adverse intraoperative events (p < 0.05), less postoperative cardiac morbidity (p < 0.05) and early graft thrombosis (p < 0.05), and fewer deaths (p = 0.08) than the control group (Table  6 ). The overall complication rate was 16 .2% in the PA catheter groups and 42.9% in the control group. We could find no difference in outcome between the SICU tune-up (group 1) compared to the PIR tune-up (group 2), i.e., the duration of the tune-up was not a significant factor.
More than 36% (36.8%) of our patients with a PA catheter (groups 1 In our study only one patient had a significant complication from insertion ofthe PA catheter. A small pneumothorax was discovered on CXR after operation in a patient from group 1. The PA catheter had been inserted through the subclavian approach in this patient. Two other patients had non-Q-wave MIs associated with the tuneup. We think this is the first report of morbidity associated with the preoperative tune-up. One patient had no clinical signs or symptoms of MI; had we not drawn cardiac enzymes before and after tune-up we would have assumed it to be an intraoperative complication. We think preoperative MI may be underreported in other clinical studies.
The cost oftechnology should be included in any benefit analysis. Schoemaker et al. 62 reported that the use of the PA catheter reduced complications, duration of hospitalization, ICU stay, duration of mechanical ventilation, and total cost when used to augment rather than simply normalize circulatory responses in a group of high-risk surgical patients. We found the use of the PA catheter to be cost neutral, i.e., the increased cost of PA monitoring and tune-up in the study groups was offset by the increased cost of treating the complications in the control group. We believe that we failed to find a significant cost difference between groups because of the severity of the underlying vascular disease. These patients commonly require lengthy hospitalization because ofthe end-organ injury incurred from their disease before the operative intervention.
The insertion ofa PA catheter is not therapeutic. While intervention on the basis of catheter-derived information is thought to be beneficial,63 at least one study refutes this presumption. 64 The PA catheter, when used by knowledgeable physicians to evaluate and optimize cardiac performance before operation, is cost neutral and improves outcome in patients undergoing peripheral revascularization procedures.
